P632: Etrasimod induction therapy in moderately to severely active Crohn's disease: results from a phase 2, randomised, double-blind substudyECCO’23 CopenhagenYear: 2023
Authors: D'Haens, G.(1)*;Dubinsky, M.C.(2);Peyrin-Biroulet, L.(3,4);Danese, S.(5);Sands, B.E.(6);Wolf, D.C.(7);Yarur, A.(8);Chiorean, M.(9);Dray, D.(10);Modesto, I.(11);Tan, H.(12);Gu, G.(13);Lopez, C.(14);Su, C.(15);Zhang, J.(16);McDonnell, A.(17);Schreiber, S.(18);Feagan, B.G.(19);Vermeire, S.(20);
(1)University of Amsterdam, Gastroenterology, Amsterdam, The Netherlands;(2)Feinstein IBD Center- Mount Sinai, Gastroenterology, New York- New York, United States;(3)University of Lorraine- Inserm- NGERE, Gastroenterology, Nancy, France;(4)Groupe Hospitalier privé Ambroise Paré - Hartmann- Paris IBD center, Gastroenterology, Neuilly sur Seine, France;(5)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;(6)Dr. Henry D. Janowitz Division of Gastroenterology- Icahn School of Medicine at Mount Sinai, Gastroenterology, New York- New York, United States;(7)Atlanta Gastroenterology Associates, Gastroenterology, Atlanta- Georgia, United States;(8)Cedars-Sinai Medical Center, Gastroenterology, Los Angeles- California, United States;(9)IBD Center- Swedish Medical Center, Gastroenterology, Seattle- Washington, United States;(10)Pfizer Inc, Global Medical Affairs- Gastroenterology, New York- New York, United States;(11)Pfizer Inc, Global Medical Affairs- Gastroenterology, Madrid, Spain;(12)Pfizer Inc, Early Internal/External Development, New York- New York, United States;(13)Pfizer Inc, Clinical Development & Operations- Inflammation & Immunology, New York- New York, United States;(14)Arena Pharmaceuticals- which was acquired by Pfizer in March 2022, Clinical Development, San Diego- California, United States;(15)Pfizer Inc, Global Product Development, New York- New York, United States;(16)Pfizer Inc, Biostatistics, New York- New York, United States;(17)Pfizer Ltd., Safety Risk, Walton Oaks- Surrey, United Kingdom;(18)University Hospital Schleswig-Holstein- Department Internal Medicine I- Kiel University, Internal Medicine, Kiel, Germany;(19)University of Western Ontario/Alimentiv Inc, Gastroenterology, London- Ontario, Canada;(20)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;
P633: Choice of first biologic in moderate to severe ulcerative colitis – a decision analysis using time-on-treatment and UK costsECCO’23 CopenhagenYear: 2023
Authors: Dhar, A.(1)*;Wilson, A.(2);Reid, V.(3);Clark, T.(4);Tibbatts, C.(5);Dallongeville, A.(6);Robertson, J.(7);Eaton, J.(8);Cranmer, H.(9);Owen, G.(8);
(1)County Durham and Darlington NHS Foundation Trust, Gastroenterology Department, Darlington, United Kingdom;(2)Belfast Health & Social Care Trust, Pharmacy Department, Belfast, United Kingdom;(3)Manchester University NHS Foundation Trust, Pharmacy Department, Manchester, United Kingdom;(4)Leeds Teaching Hospital NHS Trust, Gastroenterology Department, Leeds, United Kingdom;(5)Cardiff & Vale University Health Board, Gastroenterology Department, Cardiff, United Kingdom;(6)Takeda Pharmaceuticals International AG, Portfolio & Pipeline, Zurich, United Kingdom;(7)Takeda UK Ltd, Medical, London, United Kingdom;(8)Takeda UK Ltd, Market Access, London, United Kingdom;(9)Cranmer Consultancy, Health Economics, Sheffield, United Kingdom;
P634: Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry.ECCO’23 CopenhagenYear: 2023
Authors: Calafat Sard, M.(1,2)*;Pascual, I.(3);Nos, P.(2,4); Barrio, J.(5); Gutiérrez, A.(2,6);Martín-Arranz, M.D.(7);Ricart, E.(2,8);Gomollón, F.(2,9);Sierra Ausín, M.(10); Huguet, J.M.(11);Guardiola, J.(12);Vera, I.(13);Varela, P.(14);Iglesias, E.(15);Garcia-Planella, E.(16);de Castro , L.(17);García Sepulcre , M.F.(18); Sicilia, B.(19);Fernández-Salazar, L.(20); Calvet, X.(2,21);Muñoz, F.(22); García-López, S.(23);Bermejo, F.(24);Ramos, L.(25);Martínez Montiel, P.(26);Lorente, R.(27);Cabriada, J.L.(28);Piqueras, M.(29);Marín-Jiménez, I.(30);Esteve, M.(2,31);Mesonero, F.(32); Sesé, E.(33);P. Gisbert, J.(2,34);Márquez, L.(35);Busquets, D.(36);Pajares, R.(37);Cañete, F.(2,38);Mañosa, M.(2,38);Domènech, E.(2,38);
(1)Hospital Universitari Germans Trias i Pujol, Gastroenterology Department-IBD Unit, Badalona, Spain;(2)CIBERehd, Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas, Madrid, Spain;(3)Hospital Clínic Universitari de València, Gastroenteroloy Department, Valencia, Spain;(4)Hospital Universitario y Politécnico la Fe, Gastroenterology Department, Valencia, Spain;(5)Hospital Universitario Río Hortega, Gastroenterology Department, Valladolid, Spain;(6)Hospital General Universitario Dr Balmis de Alicante- ISABIAL, Gastroenterology Department, Alicante, Spain;(7)Hospital Universitario La Paz, Gastroenterology Department, Madrid, Spain;(8)Hospital Clinic de Barcelona, Gastroenterology Department, Barcelona, Spain;(9)Hospital Clínico Universitario "Lozano Blesa"-Instituto de Investigación Sanitaria- IIS Aragón, Gastroenterology Department, Zaragoza, Spain;(10)Complejo Asistencial Universitario de León, Gastroenterology Department, León, Spain;(11)Consorcio Hospital General Universitario de Valencia, Gastroenterology Department, Valencia, Spain;(12)Hospital Universitari de Bellvitge, Gastroenterology Department, Hospitalet del Llobregat, Spain;(13)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology Department, Majadahonda, Spain;(14)Hospital Universitario de Cabueñes, Gastroenterology Department, Gijón, Spain;(15)Hospital Universitario Reina Sofía de Córdoba, Gastroenterology Department, Córdoba, Spain;(16)Hospital de la Santa Creu i Sant Pau, Gastroenterology Department, Barcelona, Spain;(17)Hospital Alvaro Cunqueiro-Complexo Hospitalario Universitario de Vigo, Gastroenterology Department, Vigo, Spain;(18)Hospital General Universitario de Elche, Gastroenterology Department, Elche, Spain;(19)Hospital Universitario de Burgos, Gastroenterology Department, Burgos, Spain;(20)Hospital Clínico Universitario de Valladolid, Gastroenterology Department, Valladolid, Spain;(21)Corporació Sanitària Universitària Parc Taulí, Gastroenterology Department, Sabadell, Spain;(22)Hospital Universitario de Salamanca, Gastroenterology Department, Salamanca, Spain;(23)Hospital Universitario Miguel Servet, Gastroenterology Department, Zaragoza, Spain;(24)Hospital Universitario de Fuenlabrada- IdiPAZ, Gastroenterology Department, Fuenlabrada, Spain;(25)Hospital Universitario de Canarias, Gastroenterology Department, La Laguna, Spain;(26)Hospital Universitario Doce de Octubre, Gastroenterology Department, Madrid, Spain;(27)Hospital General Universitario de Ciudad Real, Gastroenterology Department, Ciudad Real, Spain;(28)Hospital Universitario de Galdakao, Gastroenterology Department, Galdakao, Spain;(29)Consorci Sanitari de Terrassa, Gastroenterology Department, Terrassa, Spain;(30)Hospital General Universitario Gregorio Marañón, Gastroenterology Department, Madrid, Spain;(31)Hospital Universitari Mutua Terrassa, Gastroenterology Department, Terrassa, Spain;(32)Hospital Universitario Ramón y Cajal, Gastroenterology Department, Madrid, Spain;(33)Hospital Universitario Arnau de Vilanova de Lleida, Gastroenterology Department, Lleida, Spain;(34)Hospital Universitario de la Princesa- IIS-Princesa- UAM- Madrid, Gastroenterology Department, Madrid, Spain;(35)Hospital del Mar de Barcelona, Gastroenterology Department, Barcelona, Spain;(36)Hospital Universitari de Girona Doctor Josep Trueta, Gastroenterology Department, Girona, Spain;(37)Hospital Universitario Infanta Sofía, Gastroenterology Department, Madrid, Spain;(38)Hospital Universitari Germans Trias i Pujol, Gastroenterology Department, Badalona, Spain;on behalf of GETECCU.
P635: Risankizumab - real world Israeli data in severe refractory IBD patientsECCO’23 CopenhagenYear: 2023
Authors: Bar-Gil Shitrit, A.(1)*;Gil, Y.(2);Israeli, E.(3);Koslowsky, B.(2);Mazuz, B.(2);Israel, I.(2);Goldenberg, R.(2);Ben-Bassat, O.(4);Weisbrud, A.(5);Ledder, O.(6);Zinger, A.(7);Ben Horin, S.(8);Goldin, E.(2);Lahat, A.(8);
(1)Shaare Zedek Medical Center, Department of Gastroenterology and Digestive Diseases, Jerusalem, Israel;(2)Share Zedek Medical Center, Department of Gastroenterology and Digestive Diseases, Jerusalem, Israel;(3)Wolfson Medical Center, Institute for Gastroenterology and Liver Diseases, Holon, Israel;(4)Barzilai Medical Center, Institute of Gastroenterology, Ashkelon, Israel;(5)Tel Aviv Sourasky Medical Center Ichilov, Institute of Gastrointestinal and Liver Diseases, Tel Aviv, Israel;(6)Share Zedek Medical Center, Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(7)Hadassah University Medical Center, Department of Gastroenterology and Liver Diseases, Jerusalem, Israel;(8)Sheba Medical Center Tel Hashomer, Institute of Gastrointestinal Diseases - Inflammatory Bowel Disease Clinic, Ramat Gan, Israel;
P636: Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn's disease: Results from the EVOLVE Expansion studyECCO’23 CopenhagenYear: 2023
Authors: Ferrante, M.(1)*;Christensen, B.(2,3);Bressler, B.(4);Brett, N.(5);Bassel, M.(5);Kamble, P.(6);Adsul, S.(6);Gianchetti, L.(7);Scharl, M.(8);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)The Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia;(3)The University of Melbourne, Department of Medicine, Melbourne, Australia;(4)St. Paul's Hospital, Division of Gastroenterology, Vancouver, Canada;(5)PPD- part of Thermo Fisher Scientific, Strategic and Scientific Affairs- PPAS and RWE, Montreal, Canada;(6)Takeda Pharmaceuticals, Gastroenterology, Cambridge, United States;(7)PPD- part of Thermo Fisher Scientific, Strategic and Scientific Affairs, Philadelphia, United States;(8)University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland;
P637: Targeting mucosal healing: dose optimization of Vedolizumab in IBD patients with inadequate endoscopic response to standard dosingECCO’23 CopenhagenYear: 2023
Authors: Dal Buono, A.(1)*;Gabbiadini, R.(1);Migliorisi, G.(1);Solitano, V.(1);Canziani, L.(2);Repici, A.(3,4);Armuzzi, A.(1,4);
(1)Humanitas Research Hospital - IRCCS, IBD Center, Rozzano- Milan, Italy;(2)University of Verona, Infectious Diseases Division- Department of Diagnostics and Public Health, Verona, Italy;(3)Humanitas Research Hospital - IRCCS, Department of Gastroenterology, Rozzano- Milan, Italy;(4)Humanitas University, Department of Biomedical Sciences, Pieve Emanuele- Milan, Italy;
P638: Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: a GETAID multicentre cohort studyECCO’23 CopenhagenYear: 2023
Authors: Fumery, M.(1)*;Defrance, A.(2);Roblin, X.(3);Altwegg, R.(4);Caron, B.(5);Hebuterne, X.(6);Carmen, S.(7);Meyer, A.(8);Nachury, M.(9);Laharie, D.(10);Nancey, S.(11);Le Berre, C.(12);Serrero, M.(13);Geyl, S.(14);Gilletta, C.(15);Ah Soune, P.(16);Duveau, N.(17);Uzza, M.(18);Abitbol, V.(19);Biron, A.(20);Tran Minh, M.L.(21);Paupard, T.(22);Vuitton, L.(23);Elgharabawy, Y.(2);Peyrin-biroulet, L.(5);
(1)Amiens University Hospital, Gastroenterology, Amiens Cedex 1, France;(2)GETAID, Getaid, Paris, France;(3)Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France;(4)Montpellier University Hospital, Gastroenterology, Montpellier, France;(5)Nancy University Hospital, Gastroenterology, Nancy, France;(6)Nice University Hospital, Gastroenterology, Nice, France;(7)GH Ambroise Paré-Hartmann, Gastroenterology, Neuilly, France;(8)Kremlin-Bicetre, Gastroenterology, Paris, France;(9)Lille University Hospital, Gastroenterology, Lille, France;(10)Bordeaux University Hospital, Gastroenterology, Bordeaux, France;(11)Lyon University Hospital, Gastroenterology, Lyon, France;(12)Nantes University Hospital, Gastroenterology, Nantes, France;(13)Marseille University Hospital, Gastroenterology, Marseille, France;(14)Limoges University Hospital, Gastroenterology, Limoges, France;(15)Toulouse university Hospital, Gastroenterology, Toulouse, France;(16)Toulon Hospital, Gastroenterology, Toulon, France;(17)Roubaix Hospital, Gastroenterology, Roubaix, France;(18)Hopital Mondor, Gastroenterology, Creteil, France;(19)Hopital Cochin, Gastroenterology, Paris, France;(20)Reims University Hospital, Gastroenterology, Reims, France;(21)Saint Louis Hospital, Gastroenterology, Paris, France;(22)Dunkerque Hospital, Gastroenterology, Dunkerque, France;(23)Besançon University Hospital, Gastroenterology, Besançon, France;GETAID
P639: Percutaneous drainage vs surgery as definitive treatment for anastomotic leak after intestinal resection in patients with Crohn's disease.ECCO’23 CopenhagenYear: 2023
Authors: Belvedere, A.(1)*;Dajti, G.(1);Larotonda, C.(1);Angelicchio, L.(1);Rizzello, F.(2);Gionchetti, P.(2);Poggioli, G.(1);Rottoli, M.(1);
(1)IRCCS Azienda Ospedaliero Universitaria di Bologna- Alma Mater Studiorum University of Bologna, Surgery of the Alimentary Tract, Bologna, Italy;(2)IRCCS Azienda Ospedaliero Universitaria di Bologna- Alma Mater Studiorum University of Bologna, IBD unit, Bologna, Italy;
P640: Serologic response and safety after third dose of the COVID-19 BNT162b2 vaccine in patients with Inflammatory Bowel DiseasesECCO’23 CopenhagenYear: 2023
Authors: Edelman-Klapper, H.(1,2)*;Rabinowitz, K.M.(1,3); Zittan, E.(4,5);Bar-Gil Shitrit, A.(6,7);Goren, I.(1,2);Avni-Biron, I.(1,2);Ollech, J.E.(1,2);Lichtenstein, L.(8);Banai-Eran, H.(1,2);Yanai, H.(1,2);Snir, Y.(1,2);Pauker, M.H.(1,2);Friedenberg, A.(1);Levy-Barda, A.(9);Segal, A.(10);Broitman, Y.(1,2);Maoz, E.(11);Ovadia, B.(12);Aharoni Golan, M.(1,2);Shachar, E.(2,13);Ben-Horin, S.(2,13);Mor, M.(11);Ben Zvi, H.(2,14);Perets, T.T.(15,16);Eliakim, R.(2,13);Barkan, R.(1);Navon, M.(17);Gal-Tanamy, M.(18);Freund, N.T.(17);Goren, S.(19);Cohen, D.(19);Dotan, I.(1,2);
(1)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(2)Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(3)Tel Aviv University, Felsenstein Medical Research Center- Sackler School of Medicine, Tel Aviv, Israel;(4)Emek Medical Center, The Abraham and Sonia Rochlin IBD Unit- Department of Gastroenterology, Afula, Israel;(5)Technion-Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa, Israel;(6)Shaare Zedek Medical Center, Digestive diseases institute, Jerusalem, Israel;(7)Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel;(8)Clalit Health Services, Gastroenterology, Petah Tikva, Israel;(9)Rabin Medical Center, Biobank- Department of Pathology, Petah Tikva, Israel;(10)Soroka University Medical Center, The Institute of Gastroenterology and Hepatology, Beer-Sheva, Israel;(11)Clalit Health Services, Gastroenterology, Tel Aviv, Israel;(12)Hillel Yaffe Medical Center, Department of Gastroenterology and Hepatology, Hadera, Israel;(13)Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;(14)Rabin Medical Center, Microbiology lab, Petah Tikva, Israel;(15)Rabin Medical Center, Division of Gastroenterology- Gastroenterology Laboratory, Petah Tikva, Israel;(16)Ariel University, Adelson School of Medicine, Ariel, Israel;(17)Tel Aviv University, Department of Clinical Microbiology and immunology- Sackler Faculty of Medicine, Tel Aviv, Israel;(18)Bar-Ilan University, Molecular Virology Lab- The Azrieli Faculty of Medicine, Safed, Israel;(19)Tel Aviv University, School of Public Health- Sackler Faculty of Medicine, Tel Aviv, Israel;the REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]
P641: Bowel Doppler Signal, the most important ultrasonographic feature in clinical practice in managing Inflammatory Bowel Diseases patientsECCO’23 CopenhagenYear: 2023
Authors: Les, A.(1)*;Cotruta, B.(1);Iacob , R.(1,2);Saizu, R.(1,2);Gheorghe, L.(1,2);Gheorghe, C.(1,2);
(1)Fundeni Clinical institute, Gastroenterology, Bucharest, Romania;(2)“Carol-Davila” University of Medicine and Pharmacy, Gastroenterology, Bucharest, Romania;
P642: Network meta-analysis: efficacy and safety of treatments for fistulising Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Chahal, J.(1);Sriranganathan, D.(2);Poo, S.(3);Lo, S.W.(4)*;Kashkooli, S.(4);Garg, M.(4,5);Segal, J.P.(4,5);
(1)Lewisham and Greenwich NHS Trust, Surgery, Lewisham, United Kingdom;(2)Whipps Cross University Hospital, Gastroenterology, London, United Kingdom;(3)Hillingdon Hospitals NHS Foundation Trust, Gastroenterology, London, United Kingdom;(4)Northern Hospital Epping, Gastroenterology, Melbourne, Australia;(5)University of Melbourne, Medicine, Melbourne, Australia;
P643: Psoriasis induced by anti-TNF therapy in Inflammatory Bowel Disease: analysis of therapeutic management and evolution of both diseases in a nationwide cohort studyECCO’23 CopenhagenYear: 2023
Authors: Sanz Segura, P.(1)*;Gomollón, F.(2);García García, S.(3);Vela, M.(4);Fernández-Clotet, A.(5);Muñoz, R.(6);García de la Filia, I.(7);García Prada, M.(8);Ferrer Rosique, J.A.(9);García, M.J.(10);de Francisco, R.(11);Arias, L.(12);Barrio, J.(13);Guerra, I.(14);Ponferrada Diaz, A.(15);P. Gisbert, J.(16);Carrillo-Palau, M.(17);Calvet, X.(18);Márquez-Mosquera, L.(19);Gros, B.(20);Cañete, F.(21);Monfort, D.(22);Madrigal, R.E.(23);Roncero, O.(24);Laredo, V.(2);Montoro, M.(25);Muñoz, C.(26);López-Cauce, B.(27);Lorente, R.(28);Fuentes, A.(29);Vega, P.(30);Martín, D.(31);Nerín de la Puerta, J.(1);Varela, P.(32);Casas-Deza, D.(33);Martínez, P.(34);Pajares, R.(35);J. Lucendo, A.(36);Domènech, E.(21);García-López, S.(33);
(1)Hospital Royo Villanova, Gastroenterology Department, Zaragoza, Spain;(2)Hospital Clínico Universitario Lozano Blesa, Gastroenterology Department, Zaragoza, Spain;(3)Hospital Universitario La Fe, Gastroenterology Department, Valencia, Spain;(4)Hospital Universitario Ntra. Sra. Candelaria, Gastroenterology Department, Santa Cruz de Tenerife, Spain;(5)Hospital Clinic de Barcelona, Gastroenterology Department, Barcelona, Spain;(6)Hospital General Universitario Dr Balmis, Gastroenterology Department, Alicante, Spain;(7)Hospital Universitario Ramón y Cajal, Gastroenterology Department, Madrid, Spain;(8)Complejo Asistencial Universitario de León, Gastroenterology Department, León, Spain;(9)Hospital Fundación Alcorcón, Gastroenterology Department, Madrid, Spain;(10)Hospital Universitario Marqués de Valdecilla- IDIVAL, Gastroenterology and Hepatology Department, Santander, Spain;(11)Hospital Universitario Central de Asturias, Gastroenterology Department, Oviedo, Spain;(12)Hospital Universitario de Burgos, Gastroenterology Department, Burgos, Spain;(13)Hospital Universitario Río Hortega, Gastroenterology Department, Valladolid, Spain;(14)Hospital Universitario de Fuenlabrada, Gastroenterology Department, Madrid, Spain;(15)Hospital Universitario Infanta Leonor, Gastroenterology Department, Madrid, Spain;(16)Hospital Universitario de La Princesa, Gastroenterology Department, Madrid, Spain;(17)Hospital Universitario de Canarias, Gastroenterology Department, Santa Cruz de Tenerife, Spain;(18)Corporació Sanitaria Parc Taulí, Gastroenterology Department, Sabadell, Spain;(19)Hospital del Mar, Servei de Digestiu, Barcelona, Spain;(20)Hospital Universitario Reina Sofía, Gastroenterology Department, Córdoba, Spain;(21)Hospital Universitari Germans Trials i Pujol and CIBERehd, Gastroenterology Department, Barcelona, Spain;(22)Consorci Sanitari de Terrassa, Gastroenterology Department, Terrasa, Spain;(23)Hospital Clínico Universitario de Valladolid, Gastroenterology Department, Valladolid, Spain;(24)Hospital General La Mancha Centro, Gastroenterology Department, Ciudad Real, Spain;(25)Hospital San Jorge, Gastroenterology Department, Huesca, Spain;(26)Hospital de Basurto, Gastroenterology Department, Bilbao, Spain;(27)Hospital General Universitario Gregorio Marañón, Gastroenterology Department, Madrid, Spain;(28)Hospital General de Ciudad Real, Gastroenterology Department, Ciudad Real, Spain;(29)Hospital Virgen de La Concha- Complejo Asistencial de Zamora, Gastroenterology Department, Zamora, Spain;(30)Complejo Hospitalario Universitario de Ourense, Gastroenterology Department, Ourense, Spain;(31)Hospital Universitario La Paz, Gastroenterology Department, Madrid, Spain;(32)Hospital Universitario de Cabueñes, Gastroenterology Department, Gijón, Spain;(33)Hospital Universitario Miguel Servet, Gastroenterology Department, Zaragoza, Spain;(34)Hospital 12 de Octubre, Gastroenterology Department, Madrid, Spain;(35)Hospital Infanta Sofía, Gastroenterology Department, Madrid, Spain;(36)Hospital General de Tomelloso, Gastroenterology Department, Ciudad Real, Spain;on behalf of the ENEIDA project of GETECCU
P644: Leucine-rich alpha 2 glycoprotein- A useful biomarker to discriminate small intestinal mucosal healing in asymptomatic CRP-negative Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Tanaka, A.(1)*;Kanmura, S.(1);Maeda, N.(1);Kuwazuru, K.(1);Komaki, F.(1);Komaki, Y.(1);Ido, A.(1);
(1)Kagoshima University Graduate School of Medical and Dental Sciences, Digestive and Lifestyle Diseases, Kagoshima city, Japan;
P645: Use of Leukocytapheresis in inflammatory bowel disease in paediatric patients. A serie of 10 cases.ECCO’23 CopenhagenYear: 2023
Authors: Martinez Navarro, G.(1)*;Palomino Pérez, L.M.(1);Velasco Rodríguez-Belvís, M.(1);Cañedo Villarroya, E.(1);De la Mano Hernández, A.(1);Dominguez Ortega, G.(1);Martínez Pérez, J.(1);Martín Fernández, C.(1);Di Campli Zaghlul, M.(1);García Hernández, P.(1);Sánchez Llorente, P.(1);Muñoz Codoceo, R.A.(1);
(1)Hospital Infantil Universitario Niño Jesús, Gastroenterology and Nutrition, Madrid, Spain;
P646: Relative association of bowel urgency clinically meaningful improvement and bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Work Productivity and Activity Impairment Scores in patients with moderately-to-severely active Ulcerative Colitis: An analysis from LUCENT-1 and LUCENT-2 Phase 3 clinical trials.ECCO’23 CopenhagenYear: 2023
Authors: Sands, B.E.(1)*;Feagan, B.G.(2,3);Gibble, T.H.(4);Keohane, A.(4);Eastman, W.J.(4);Traxler, K.A.(4);Schreiber, S.(5);Jairath, V.(2);Armuzzi, A.(6);
(1)Icahn School of Medicine, Gastroenterology, New York, United States;(2)Western University, Epidemiology & Biostatistics, London- Ontario, Canada;(3)Alimentiv Inc., Epidemiology & Biostatistics, London- Ontario, Canada;(4)Eli Lilly and Company, Immunology, Indianapolis, United States;(5)University Hospital Schleswig-Holstein- Kiel University, Department Internal Medicine, Kiel, Germany;(6)Humanitas Research Hospital, Gastroenterology, Milan, Italy;
P647: Outcomes following the use of vedolizumab first line versus second line in Ulcerative Colitis: a single centre experienceECCO’23 CopenhagenYear: 2023
Authors: Almas, S.(1);Al-Talib, I.(1)*;Rahman, C.(1);Ansari, M.(1);Jones, J.(1);Slater, J.(1);King, D.(1);De Silva, S.(1);
(1)Russells Hall Hospital, Gastroenterology, Dudley, United Kingdom;
P648: Effectiveness of Biologic Therapies in Decreasing Risk of Hospitalization and Surgery, Maintaining Steroid Free Remission and Achieving Mucosal Healing in Inflammatory Bowel Disease; Real World Data.ECCO’23 CopenhagenYear: 2023
Authors: Shehab, M.(1)*;Abdullah, I.(1);Alostad, W.(1);Marei, A.(1);Alfadhli, A.(1);
(1)Mubarak Al-Kabeer Hospital, Internal medicine, Kuwait, Kuwait;
P649: Does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?ECCO’23 CopenhagenYear: 2023
Authors: Carbery, I.(1)*;Lin, S.(2);Chanchlani, N.(2);Janjua, M.(2);Nice, R.(3);McDonald, T.J.(3);Bewshea, C.(4);Kennedy, N.A.(2);Ahmad, T.(2);Goodhand, J.R.(2);Selinger, C.P.(1);
(1)Leeds Teaching Hospitals NHS Trust, Leeds Gastroenterology Institute, Leeds, United Kingdom;(2)University of Exeter, Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, Exeter, United Kingdom;(3)Royal Devon and Exeter NHS Foundation Trust, Biochemistry- Exeter Clinical Laboratory International, Exeter, United Kingdom;(4)Royal Devon and Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom;
P650: Integrin expression patterns of patients with IBD treated with vedolizumab.ECCO’23 CopenhagenYear: 2023
Authors: Kokkotis, G.(1)*;Chalakatevaki, K.(1);Papathanasiou, E.(2);Tzanoudaki, M.(3);Kane, R.(3);Liatsis, M.(3);Zampeli, E.(2);Michopoulos, S.(2);Bamias, G.(1);
(1)3rd Academic Department of Internal Medicine- University of Athens- Sotiria Hospital, GI Unit, Athens, Greece;(2)Alexandra General Hospital, Gastroenterology Department, Athens, Greece;(3)"Aghia Sophia" Children's Hospital, Department of Immunology & Histocompatibility, Athens, Greece;
P651: Comparison of Adverse Events of SARS-CoV-2 Vaccination between Patients with Inflammatory Bowel Disease and Healthcare WorkersECCO’23 CopenhagenYear: 2023
Authors: Kim, J.(1)*;Sagong, M.(1);Lee, Y.J.(1);Kim, K.O.(2);Kim, E.S.(3);Kim, E.Y.(4);Jang, B.I.(2);
(1)Keimyung University School of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(2)Yeungnam University College of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(3)Kyungpook National University School of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;(4)Daegu Catholic University of School of Medicine, Department of Internal Medicine, Daegu, Korea- Republic Of;